BFRI — Biofrontera Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1858685 ·
Last close
$1.46
Market Cap
$21.68M
52W High
$1.55
52W Low
$0.79
ADV30
470,102
Next earnings
2026-11-11
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 10,084,000 7,968,000 -3,928,000 -4,752,000 24,787,000 6,317,000 18,717,000
Dec 2025 17,100,000 14,091,000 4,559,000 5,640,000 28,564,000 6,392,000 18,084,000
Sep 2025 6,988,000 4,943,000 -6,278,000 -6,649,000 15,415,000 3,417,000 17,996,000
Jun 2025 9,030,000 6,388,000 -5,079,000 -5,324,000 20,142,000 7,239,000 24,810,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-9,314,000
Investing CF
$2,996,000
Financing CF
$10,850,000
CapEx
$-10,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.12
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-132,697,000
Inventory
$1,231,000
Receivables
$3,879,000
ST Investments
$9,000
EBIT TTM
$-10,245,000
Pretax Income TTM
$-11,058,000
Interest Exp TTM
$401,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$46,175,000
EBITDA
$-5,968,000
Free Cash Flow
$-7,597,750
Enterprise Value
$24,818,492
Total Cash
$4,667,000
Total Debt
$7,504,000
Shares Out
14,852,359
Trailing EPS
$-0.43
Book Value
$0.42
ROE
-988.4%
ROA
-17.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 41,705,000 -11,348,000 -10,536,000 28,564,000 18,084,000 -13,361,000
Dec 2024 37,321,000 -17,210,000 -17,759,000 22,101,000 17,668,000 -10,270,000
Dec 2023 34,071,000 -22,577,000 -20,131,000 27,932,000 23,139,000 -24,895,000
Dec 2022 28,674,000 -22,381,000 -640,000 50,884,000 27,006,000 -16,199,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.43

Peers — same industry

TickerNameMarket CapLastDaily %
COCP Cocrystal Pharma, Inc. $21.38M $1.11
NEUP Neuphoria Therapeutics Inc. $21.35M $3.95
ALLR Allarity Therapeutics, Inc. $22.12M $1.39
ABVC ABVC BIOPHARMA, INC. $22.39M $0.84
CELU Celularity Inc $22.43M $0.77

News headlines (Yahoo Finance, 1h cache)

Biofrontera (BFRI) Q2 2026 Earnings Call Transcript
2026-08-20 15:58 · Yahoo
Biofrontera Inc (BFRI) (Q2 2026) Earnings Call Highlights: Strong Ameluz Growth Drives Revenue ...
2026-08-13 23:03 · Yahoo
Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates
2026-08-13 14:10 · Yahoo
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
2026-08-13 12:51 · Yahoo
Biofrontera (BFRI) Q1 2026 Earnings Transcript
2026-06-02 17:16 · Yahoo
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
2026-05-21 13:15 · Yahoo
Biofrontera Inc (BFRI) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
2026-05-14 23:04 · Yahoo
Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates
2026-05-14 13:25 · Yahoo
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
2026-05-14 11:30 · Yahoo
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
2026-05-08 20:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.